A scientist and entrepreneur. Filip acquired 15+ years of research experience, both in Poland and the USA, and over 10 years of experience in building start-ups. He received his Ph.D. in biochemistry from the University of Wroclaw in the Department of Protein Engineering. Next, he trained at the Institute of Molecular Medicine at Health Science Center in Houston, USA, in the laboratory of Nobel Prize laureate Professor Ferid Murad, where he investigated signaling proteins related to cardiovascular diseases. He obtained his executive MBA diploma at the Polish-American School of Business. Filip has broad experience in biotechnology-related businesses and is involved in many R&D projects associated with the development of new drugs and medical devices.
Our team
The foundation upon which Pure Biologics is built comprises a group of exceptionally talented and energetic people who pursue every project and idea with passion. Our employees constitute a diverse and multidisciplinary team with extensive experience gained in domestic and international institutions alike. Each and every person who conceptualizes ideas and actively participates in implemented projects, ultimately determines the stability of the team and its full engagement in achieving set goals. Highly qualified staff, years of experience and a focus on effective cooperation enable us to reach successive milestones of R&D projects and to execute contracted research activities.
Romuald Harwas graduated from the Faculty of Management at the Cracow University of Economics, majoring in accounting. He has several years of experience in finance. Romuald began his career from the position of financial analyst, was a management accountant, financial controller and then CFO and a board member of limited companies. In Poland, he worked at TVN, Luxmed and Synektik. Romuald spent more than six years abroad, working for among others, Australian syndicate Bradken. He has led transition processes of companies from NewConnect to the main market of the WSE and cooperated with various investment funds. Romuald is a specialist in management, accounting and economic analysis.
Pieter Spee graduated as medical biologist/biochemist and later specialized in immunology and oncology during his Ph.D. in Amsterdam. He worked at Novo Nordisk, where he went from a scientist dealing with cancer biology, angiogenesis, and immunology, through positions of principal investigator, project manager, up to Director of the NK cell biology department and then taking the position of Director and Scientific Director of the Department of Translational Immunology. At Novo Nordisk he took part in the development of Lirilumab and Monalizumab antibodies that are now in late-stage clinical development. He has served, among others, as CTO of FibroTX in Estonia (skin diagnostics), and CSO of Tikomed in Sweden (preclinical and clinical development of IBSOLVMIR for the improvement of pancreatic islet transplantation). He is a co-inventor of 7 patents in the field of antibodies and has authored almost 30 scientific publications.
A graduate of the Faculty of Law and Administration at Wroclaw University, majoring in Law, he is registered on the list of legal advisors of the Wroclaw Regional Chamber of Legal Advisors, a member of supervisory boards of companies operating in Lower Silesia, a representative of the State Treasury on supervisory boards of companies undergoing privatisation. He gained his professional experience as a credit specialist in Pomorski Bank Kredytowy S.A. (1993) and First Commercial Bank S.A. (1994), and then as a leasing specialist in European Leasing Fund S.A. (1995). Between 1997 and 2012, he ran a business under the name of Kancelaria Prawa Gospodarczego Mirosław Ciućman, providing legal services to business entities – natural persons and legal entities, as well as representation in court in business disputes. Between 2006 and 2012 he co-operated with TNT Consulting Sp. z o.o., an authorised advisor on the New Connect market of the Warsaw Stock Exchange. Since 2015 he has been cooperating with Dr. Ziembiński & Partners Sp. z o.o., a law firm based in Poznań, in the area of representing creditors and debtors in insolvency proceedings before the commercial courts. Member of the Supervisory Board of Przychodnia na Biskupinie Sp. z o.o. since 2020.
Dr. Pawel Wisniewski is a graduate of the Warsaw University of Life Sciences. In 2009, he received his PhD in molecular biology from the Marceli Nencki Institute of Experimental Biology of the Polish Academy of Sciences in Warsaw. He gained experience successively as a researcher at the International Institute of Molecular and Cell Biology in Warsaw and the Institute of Molecular Genetics of Montpellier. From 2012 to 2016, Project Manager at Adiuvo Investments S.A.; from 2015 to 2016, Advisor to the Management Board at Eastern European Investment Management Sp. z o.o. In total, he has over twelve years of experience in biotechnology business development, technical due diligence, technology transfer, drug discovery, intellectual property protection, strategy development and implementation, which he gained through his leadership positions at Helix BioPharma Corp., Toronto (2016-2017), Healthnomic S.A. (2022-2023), Helix Immuno-Oncology S.A. (2015-2020). Since 2011, he has served as CEO of Institute of Genetic Analyses Ltd. INAGEN, and Vice President of the Board at 4Cell Therapies S.A. since 2020.
Graduate of the University of Wrocław, Ph.D. in biochemistry, biotechnologist, manager with over 17 years of experience in the management of new product development projects in the OTC and FMCG segments and implementation of innovative technologies, carried out as part of projects co-financed by EU funds. She has experience in the preparation, implementation and settlement of grant projects co-financed, inter alia, from NCBR and ABM, management of intellectual property of companies and R&D, Quality Control and Quality Assurance departments. Member of the Board of Directors of Oleofarm sp. z o.o. from 2015 to 2019 and Vice President and President of the National Council for Supplements and Nutrients from 2013 to 2018, on behalf of which she was responsible, among other things, for contacts with regulatory authorities at national and European level and implementation of the first industry self-regulation in advertising in Poland and Europe. She is currently Chief Operating Officer of WPD Pharmaceuticals sp. z o.o., where she is in charge of the following areas: intellectual property rights, human resources, accounting, including supervision of financial audits, budgeting and PR and IR.
Prof. dr hab. Julia Bar is a head of the Immunopathology and Molecular Biology Division of Wroclaw Medical University. She specializes in immuno-oncology, cancer biology and in regenerative medicine and tissue engineering experimental research. She conducts research on cancer cell resistance to chemotherapy and on stem cell-based biological implants. Her scientific achievements include two patents, several dozen research papers and almost two hundreds conference presentations.
Dr hab. Mariusz Czekala is a professor and lecturer at the WSB University in Wroclaw. He is a recognized expert in the field of quantitative disciplines i.e. money theory in time, elements of statistics and econometrics, fundamental and technical analysis, portfolio analysis, and stock quotation systems. He specializes in building econometric models for valuation of capital companies and investments. He published a number of scientific papers and monographs, including in the field of fundamental and technical analysis of financial instruments, effectiveness of investment funds and financial risk protection instruments.
Professor Jacek Otlewski is an experienced biochemist, biophysicist and molecular biologist, a researcher of the structure and function of proteins. For many years, he has been developing phage display technology for antibodies and other protein structures. His research interests are related to targeted therapy and the development of conjugates of therapeutic proteins and cytostatics in the treatment of cancer. He supervised several dozens of doctorates, authored over 150 publications and several patents. He is a member of the Polish Academy of Sciences, European Molecular Biology Organization and Academia Europaea. Since 1994, he is the head of the Protein Engineering Department and in the years 2006-2012 he served as dean of the Faculty of Biotechnology of the University of Wroclaw.
Dr. Waldemar Priebe is Professor of Medicinal Chemistry at the Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, in Houston (USA). His career developed in the translational space between research on novel approaches to drug design, preclinical studies, as well as industry and business. Waldemar Priebe is a cofounder of numerous companies, a few of which are in the NASDAQ index. He has also served as a consultant to numerous pharmaceutical companies. Dr. Priebe’s research focuses on metabolic pathway inhibition in cancer. Results and inventions of Dr. Priebe are published in more than 200 scientific articles and protected by over 50 patents.
Dr. Radosław Zagożdżon graduated from the Faculty of Medicine of the Medical University of Warsaw. He was a postdoctoral fellow and worked at Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston (USA) and at University College Dublin in Ireland. Since 2017, he has been the head of the Department of Clinical Immunology at the Institute of Transplantation of the Medical University of Warsaw, at the same time working as a physician in the Department of Immunology, Transplantology and Internal Diseases of the Infant Jesus Clinical Hospital. He is also a scientific consultant in the Department of Bioinformatics at the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. Dr Zagożdżon has several years of medical and scientific experience, including conducting animal research to study the effects of new compounds on the immune system and in cancer.
Professor Bogusław Paradowski is a specialist in neurology with several years of experience. He works among others in the Neurology Clinic at the University Clinical Hospital in Wrocław, where he is a deputy head of the clinic. His scientific interests encompass demyelination diseases, including multiple sclerosis, vascular diseases and dementia. Thanks to his initiative, nine medical centers were established in Lower Silesia, where patients suffering from multiple sclerosis are treated with modern I-line methods. For over 20 years, professor Paradowski has been Lower Silesian Voivodeship chief consultant in the field of neurology. Since 2017, he has held the position of associate professor at the University of Medical Sciences in Wroclaw.
Professor Konrad Rejdak, M.D. is a specialist in neurology. He is head of the Department and Clinic of Neurology at the Faculty of Medicine at the Medical University of Lublin, and the president-elect of the Polish Society of Neurology. Professor Rejdak is also a member of the Scientific Panel of the European Academy of Neurology, as well as numerous scientific societies, both Polish and international (including the American Academy of Neurology, International League Against Epilepsy, ECTRIMS). He is also a voivodeship consultant in the field of neurology in the Lubelskie Voivodeship.
During its decade of operation, Pure Biologics has built a team of experts both in scientific fields – biotechnology, protein engineering, molecular biology, biophysical analysis, cell biology and antibody & aptamer discovery,
as well as from the sectors of business support and management.
A majority of our staff has international experience acquired while working in various places. Our team of specialists lies at the heart of our R&D projects, and we are certain that no challenge is insurmountable for us.